JP2020105186A5 - - Google Patents

Download PDF

Info

Publication number
JP2020105186A5
JP2020105186A5 JP2020034938A JP2020034938A JP2020105186A5 JP 2020105186 A5 JP2020105186 A5 JP 2020105186A5 JP 2020034938 A JP2020034938 A JP 2020034938A JP 2020034938 A JP2020034938 A JP 2020034938A JP 2020105186 A5 JP2020105186 A5 JP 2020105186A5
Authority
JP
Japan
Prior art keywords
disease
neurodegenerative disorder
disorder
medicament according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020034938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020105186A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020105186A publication Critical patent/JP2020105186A/ja
Publication of JP2020105186A5 publication Critical patent/JP2020105186A5/ja
Pending legal-status Critical Current

Links

JP2020034938A 2013-03-15 2020-03-02 新規使用 Pending JP2020105186A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799603P 2013-03-15 2013-03-15
US61/799,603 2013-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018200930A Division JP2019031544A (ja) 2013-03-15 2018-10-25 新規使用

Publications (2)

Publication Number Publication Date
JP2020105186A JP2020105186A (ja) 2020-07-09
JP2020105186A5 true JP2020105186A5 (enExample) 2020-08-20

Family

ID=51538509

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503395A Withdrawn JP2016518343A (ja) 2013-03-15 2014-03-17 新規使用
JP2018200930A Withdrawn JP2019031544A (ja) 2013-03-15 2018-10-25 新規使用
JP2020034938A Pending JP2020105186A (ja) 2013-03-15 2020-03-02 新規使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016503395A Withdrawn JP2016518343A (ja) 2013-03-15 2014-03-17 新規使用
JP2018200930A Withdrawn JP2019031544A (ja) 2013-03-15 2018-10-25 新規使用

Country Status (5)

Country Link
US (4) US9545406B2 (enExample)
EP (2) EP2968338B1 (enExample)
JP (3) JP2016518343A (enExample)
ES (2) ES2717688T3 (enExample)
WO (1) WO2014145617A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3970719A1 (en) 2016-09-12 2022-03-23 Intra-Cellular Therapies, Inc. Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder
JP7401442B2 (ja) * 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
KR20210013214A (ko) * 2018-05-25 2021-02-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
WO2019241141A1 (en) * 2018-06-11 2019-12-19 The United States Government As Represented By The Department Of Veterans Affairs Method for treating myocardial reperfusion injury using an inhibitor of the cyclic nucleotide phosphodiesterase pde1
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US11628171B2 (en) * 2019-03-13 2023-04-18 Children's Medical Center Corporation Method for treating brain or nerve injury
EP4025202A4 (en) * 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
CN114340636A (zh) 2019-09-03 2022-04-12 细胞内治疗公司 治疗方法
EP4065573A4 (en) * 2019-11-27 2023-12-27 Intra-Cellular Therapies, Inc. PROCEDURE FOR TREATMENT
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
WO2023147484A1 (en) * 2022-01-27 2023-08-03 Intra-Cellular Therapies, Inc. Novel compositions
IL316924A (en) 2022-05-18 2025-01-01 Intra Cellular Therapies Inc Novel methods
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025255013A1 (en) * 2024-06-03 2025-12-11 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032638B2 (ja) 1976-09-01 1985-07-29 武田薬品工業株式会社 ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体
JPS58500966A (ja) 1981-04-22 1983-06-09 ビイク　グルデン　ロンベルク　ヒエ−ミツシエ　フアブリ−ク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピラゾロ〔３，４−ｄ〕ピリミジン、その製法及びこれを含有する医薬品
US4469868A (en) 1982-05-24 1984-09-04 Warner-Lambert Company Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
US4603203A (en) 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
KR920004437B1 (ko) 1989-09-12 1992-06-05 삼성전자 주식회사 금전등록기의 거래선 관리방법
ZA914727B (en) 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
NZ262797A (en) 1993-02-26 1997-08-22 Schering Corp Polycyclic guanine derivatives, purine and pyrimidine precursors; medicaments
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
US6133273A (en) 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
US6459908B1 (en) 1998-12-31 2002-10-01 Qwest Communications International Inc. Method and system for supporting wireless features in a Generic C wireline architecture
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1222190A1 (en) 1999-10-11 2002-07-17 Pfizer Limited 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
ATE298238T1 (de) 2001-03-16 2005-07-15 Pfizer Pyrazolo(4,3-d)pyrimidinon-verbindungen als cgmp pde-inhibitoren
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
MXPA04001891A (es) 2001-08-28 2004-06-15 Schering Corp Inhibidores policiclicos de guanina fosfodiesterasa v.
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
WO2003042216A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
WO2003070174A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20050153372A1 (en) 2002-02-21 2005-07-14 Paul Greengard Compositions and method for regulation of calcium-dependent signaling in brain
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US7666843B2 (en) 2002-09-27 2010-02-23 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
WO2004031375A2 (en) * 2002-10-01 2004-04-15 Bayer Healthcare Ag Regulation of human 3’, 5’ cyclic nucleotide phosphodiesterase pde1c
EP1604202A2 (en) * 2003-03-11 2005-12-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004087906A1 (en) 2003-03-31 2004-10-14 Pfizer Products Inc. Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
BRPI0414087A (pt) 2003-09-05 2006-10-31 Neurogen Corp composto, métodos para tratar um distúrbio, para demostrar a presença de receptores de crf em amostras de célula ou tecido, e para inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem
US20050287665A1 (en) * 2004-06-23 2005-12-29 Henrich Cheng Method for inducing neural differentiation
US20060052856A1 (en) * 2004-09-08 2006-03-09 Kim Daniel H Stimulation components
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
JP5453086B2 (ja) 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20070286890A1 (en) 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
US9198924B2 (en) 2006-11-13 2015-12-01 Intra-Cellular Therapies, Inc. Organic compounds
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
CN104370920A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
WO2009073210A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2010065148A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EA201170771A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
EP2400970A4 (en) * 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
RU2591194C2 (ru) 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2012171016A1 (en) * 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
CA2845039A1 (en) * 2011-08-18 2013-02-21 Shire Ag Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9598426B2 (en) 2013-03-15 2017-03-21 Intra-Cellular Therapies, Inc. Organic compounds
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
EP3970719A1 (en) 2016-09-12 2022-03-23 Intra-Cellular Therapies, Inc. Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder

Similar Documents

Publication Publication Date Title
MX2022010044A (es) Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
RU2017112989A (ru) Соединения и способы
JP2016528301A5 (enExample)
HRP20191055T1 (hr) Terapeutska sredstva za neurodegenerativne bolesti
JP2008534627A5 (enExample)
JP2014517050A5 (enExample)
PH12020550631A1 (en) New catecholamine prodrugs for use in the treatment of parkinson`s disease
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
JP2017511339A5 (enExample)
JP2022515293A5 (enExample)
JP2022539152A5 (enExample)
MX2019002444A (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
BR112019024851A2 (pt) agente para evitar ou tratar atrofia cerebral
JP2018502163A5 (enExample)
BR112019024878A2 (pt) Agente para prevenção ou tratamento de tauopatia
IL305576B2 (en) Ovicetafib for the treatment of dementias
EP3695847A4 (en) FINE JET ESSENTIAL OIL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISEASES
Kummer et al. Dopamine dysregulation syndrome in Parkinson's disease: case report
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
EP3838272A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE
Cakarer et al. Peripheral facial nerve paralysis after upper third molar extraction
FI3909568T3 (fi) Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin
Yovtcheva et al. Reemergence of tardive dyskinesia after discontinuation of clozapine treatment